Studying risk factors for acute crisis in people with pulmonary hypertension
Studies what causes and predicts severe crisis in people with pulmonary hypertension.
Plain-language title generated from the registry record
Registry title: Risk Factor Assessment for Acute Pulmonary Hypertension Crisis
Key facts
- Where
- Beijing, Guangzhou, Kunming, and Shanghai, ChinaSee the 4 sites
Where in China
- Peking Union Medical College HospitalBeijing, ChinaTaking people
- Guangdong Province People's HospitalGuangzhou, ChinaTaking people
- Yan'an Affiliated Hospital of Kunming Medical UniversityKunming, ChinaTaking people
- Shanghai Pulmonary HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07653958
- Record updated
- 22 June 2026
- Original description
The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are:Read full original descriptionShow less
Research on the Clinical Risk Factor Assessment System for Acute Pulmonary Hypertension Crisis and Its Mortality
The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are:
What are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC?
A multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.
Inclusion: Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter; At least once per year of follow-up data collection record.
Exclusion: Receiving medications with significant influence on hemodynamics; Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc; Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc; Patients with missing baseline or follow-up data.